Drug-resistant herpes: cidofovir gel in limbo. Interview with Jay Lalezari, M.D. Interview by John S. James.
Lalezari
J
J
D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077404:Cidofovir; D002986:Clinical Trials as Topic; D003596:Cytosine / Q000008:administration & dosage / Q000627:therapeutic use*; D017277:Drug Approval; D004352:Drug Resistance, Microbial; D005782:Gels; D006566:Herpesviridae Infections / Q000188:drug therapy*; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D005782:Gels; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir